For example, data from Eastern Cooperative Oncology Trial E1900 was updated recently (American Society of Hematology, 2014, abstracts) and benefit of high doses of daunorubicin in AML patients with FLT3-TD, NPM1, and DNMT3A mutant was confirmed after a long time follow-up. Here, FLT3 is linked to acute myeloid leukemia.